Collegium Pharmaceutical, Inc.

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
32.18 ^USD	-0.56%		-0.06%	+4.55%

07-01	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index	CI
07-01	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index	CI

Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index

July 30, 2024

Latest news about Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index	06-30	CI
Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index	06-30	CI
Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity	06-13	MT
Collegium Pharmaceutical, Inc. Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise	06-13	CI
Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	06-07	MT
Collegium Pharmaceutical Insider Sold Shares Worth $814,180, According to a Recent SEC Filing	06-05	MT
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program	05-13	MT
Needham Downgrades Collegium Pharmaceutical to Hold From Buy	05-10	MT
Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	05-10	MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated	05-10	MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47	05-09	MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	05-09	CI
Transcript : Collegium Pharmaceutical, Inc., Q1 2024 Earnings Call, May 09, 2024	05-09
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.	05-09	CI
Collegium Announces CEO Transition	05-09	CI
Collegium Announces President and Board Changes	05-09	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER	04-29	CI
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	04-11	MT
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics	04-03	CI
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	02-26	MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	02-26	MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase	02-23	MT
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26	02-22	MT

Chart Collegium Pharmaceutical, Inc.

Duration

Period

More charts

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Sector

Pharmaceuticals

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Collegium Pharmaceutical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

32.18 USD

Average target price

41 USD

Spread / Average Target

+27.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
COLLEGIUM PHARMACEUTICAL, INC.	+4.55%	1.05B
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals